Microbiome Test for the Detection of Colorectal Polyps and Cancer

Metabiomics Neoplasia Clinical Research Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02141945

Enrollment

260

Registered

2014-05-20

Start date

2014-03-31

Completion date

2017-03-01

Last updated

2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Colorectal Neoplasms

Keywords

Cancer, Colon Cancer, Colorectal Cancer, Neoplasm, Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Colonic Diseases, Digestive System Diseases, Gastrointestinal Diseases, Intestinal Diseases, Rectal Diseases

Brief summary

The purpose if this study is to measure the sensitivity, specificity and accuracy of the Metabiomics Colon Polyp and Colorectal Cancer Assay for the non-invasive detection of colon polyps or colorectal cancer.

Detailed description

The purpose of this study is to conduct clinical research to investigate the association of the gut microbiome with colonic neoplasia. In this study patients will supply samples of their gut microbiome prior to scheduled colonoscopy; the relative abundance of microbes from those samples will be used to predict the presence or absence of colon polyps or colorectal cancer. Microbiome based predictions from blinded samples will be compared with colonoscopy and pathology results to quantify the sensitivity, specificity and accuracy (reported as %) of the Metabiomics Colon Polyp and Colorectal Cancer Assay for colon polyps. The limited sample size is anticipated to be insufficient to quantify sensitivity to colorectal cancer.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Male or female, * Age: 45-80 years, * Patients undergoing polyp surveillance or screening colonoscopy who are ASA Class 1-3. No ASA Class 4 or 5 will be included.Footnote * All ethnic and racial groups will be included, * Able to comprehend, sign, and date the written informed consent form (ICF), * Able to give informed consent in English.

Exclusion criteria

* History of Inflammatory Bowel Disease * Inability to schedule the colonoscopy within 60 days of the initial stool sample * Colonic pathology that in the opinion of the endoscopist could interfere with the accuracy of the colonoscopy. Examples include: colonic stricture, poor preparation, obstructing tumor. * ASA class 4 or greater * Vulnerable subjects. Students, nursing home residents, institutionalized patients, and those with psychological or physical incapacity.

Design outcomes

Primary

Measure	Time frame	Description
Performance of Metabiomics Colon Polyp and Colorectal Cancer Assay	1 year	Microbiome based predictions from at least 100 blinded samples will be compared with colonoscopy and pathology results to quantify the sensitivity, specificity and accuracy (reported as %) of the Metabiomics Colon Polyp and Colorectal Cancer Assay for colon polyps. The limited sample size is anticipated to be insufficient to quantify sensitivity to colorectal cancer.

Countries

United States

Outcome results